Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...

In a groundbreaking new study, the active ingredient in Ozempic was found to be so effective at treating arthritis that ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...